Health Economics and Outcomes Research (HEOR)
Demonstrate a treatment’s value and quantify associated outcomes with innovative HEOR-based solutions
Schedule Free Demo Industry Collaboration
Health Economics & Outcomes Research
With increasing pressure to control the rising cost of healthcare, there’s a greater need to demonstrate the value of health care treatments in addition to their efficacy. HEOR analytics plays an increasingly vital role in a drug’s approval and reimbursement with payers. HEOR analyses allow us to evaluate the economics of a given treatment and quantify the associated outcomes.
Key Offerings
Patient-Level
Simulation
Test and analyze complex treatment outcomes on various types of patients with our patient-level simulations, supported with real world and clinical trials data.
Cost Effectiveness
Models
Ensure cost-effectiveness to maximize chances of drug approval, with our customized and analytically rigorous models. These models are transparent and adaptable for global stakeholders.
Clinical Trial
Simulations
Make informed decisions around clinical trial design with Axtria’s trial simulations. Ensure cost-effective analyses and reduced iterations across varying scenarios for continued product benefits.
Burden of Disease
Analysis
Get detailed insights into the cost, morbidity, mortality and unmet needs associated with multiple treatment options, to maximize patient well-being and cost-effectiveness
Real World Data
Experience
Experience real-world evidence-based insights, using real-world and anonymized patient-level data to make educated decisions on various treatment options and their implied outcomes.
Managed Markets and
HEOR Analytics
Unveil market complexities with Axtria’s deep domain and strategy consulting expertise in managed markets, and hands-on experience with traditional and emerging datasets in this space.
Axtria Research Hub
Executive Insights And Perspectives On The Life Sciences Industry.
Customer Success Stories
Explore How Axtria Helps Life Sciences Businesses Achieve Commercial Success.
Diagnosis of a rare disease, lack of therapies, and small patient populations all lead to significant challenges in rare disease management and support of these patients. ...
COVID-19 has drastically reduced the interactions between the physician and the sales representative as many healthcare organizations (HCOs) have placed sweeping restrictions on sa ...
The financial significance of contracts with payers makes it imperative for pharmaceutical companies to evaluate contracting decisions thoroughly. To quantify the impact of contrac ...
